Dariohealth reports first quarter financial and operating results

Sequential quarterly growth in revenue to $7.07 million gross profit margin improving to 44.8% sequentially in the first quarter of 2023, up from 40.1% of revenues in the fourth quarter of 2022 non-gaap gross margin was 60.1% of revenues for the first quarter of 2023, up from 58.1% of revenues in the fourth quarter of 2022 reduced cash used in operating activities in the first quarter to only $4.76 million further reduced net loss to $12.8 million in q1 2023, versus $15.9 million in q1 2022, and $12.6 million in q4 2022 expanded strategic relationships by signing with amwell and the first account through our relationship with sanofi, a national pharmacy benefits manager announced the presentation of the first sanofi of dario data which showed statistically significant reduction in all-cause health care resource utilization, including a 23.5% reduction in hospitalizations. cash balance as of the end of q1 of $38.8 million proforma cash balance as of the end of q1 inclusive of the private placement offering proceeds and the refinanced loan was $61 million company to host investor conference call and webcast at 8:30 a.m.
DRIO Ratings Summary
DRIO Quant Ranking